About US
Contact us
-
Mylan CFO jetting off to Israel for stock exchange meeting: ReutersMylan ($MYL) is sending its CFO, John Sheehan, on the road in Israel. That's the home country of its spurned suitor Teva ($TEVA), but it's also one place where its takeover target Perrigo ($PRGO) is p2015/6/24
-
Top-spending pharma advertisers for 2016: J&J, Pfizer, Roche and NovartisPharma ad budgets may be set to dip overall in 2016, but the industry's big spenders will still be shelling out $2 billion each--or more--to promote their drugs, according to an annual spending study.2015/6/23
-
Generics maker Alvogen eyes faster growth after CVC-led buyoutIn the latest bit of pharma M&A, a group of investment funds teamed up to buy generics makerAlvogen. A consortium led by CVC Capital Partners snapped up a majority stake in the NJ-based company, i2015/6/23
-
U.S. court nixes Teva's Copaxone patent--againIt's been a long legal road forCopaxone, and one that took yet another turn Thursday as the U.S. Court of Appeals struck down the drug's patent for the second time. In January, the U.S. Supre2015/6/19
-
Valeant said to step up talks on potential $800M deal for Egypt's AmounLast month, reports said Valeant ($VRX) was eyeing up one of Egypt's largest drugmakers. Now, word has it, those talks have progressed, and the Canadian pharma could be ready to pull the trigger in th2015/6/18
-
Bad news for AbbVie: Humira copies expected to rack up biggest biosim salesHere's something AbbVie ($ABBV) doesn't want to hear: Industry watchers expect biosimilars for its top moneymakerHumirato be the most successful copycat biologics launched in the U.S. and Europe. Tha2015/6/17
-
Drug price hawk CVS Health and the case of the $44,000 nutrition supplementCVS Health ($CVS) may be staring down pricey hep C drugs and forthcoming PCSK9 meds, but capsules of powdered resveratrol? Not so much. The pharmacy benefits manager recently approved a $44,000 claim2015/6/17
-
Branded pharma worries, generics makers cheer as trade pact hits snag in CongressTheTrans-Pacific Partnershiptook it on the chin Friday when the U.S. House voted against a key assistance program for workers displaced by global trade. That move throws a wrench into U.S. efforts to2015/6/16
-
You want to quash 'Low-T' overprescription, FDA? Quash DTC ads, experts urgeAfter warning that casual use oftestosterone medscan cause heart attack and stroke, theFDAhas finally put its foot down to curb overprescribing of the drugs. But some say the agency needs to go furthe2015/6/16
-
Are CV studies worth it for diabetes meds? After Merck and Sanofi's recent successes, some say noEarlier this week, diabetes drugmakers Merck ($MRK) and Sanofi ($SNY) rolled out data showing their meds--Januvia and Lyxumia, respectively--passed heart safety tests, turning up no red flags in postm2015/6/15